Literature DB >> 22464995

Imaging techniques for local recurrence of prostate cancer: for whom, why and how?

O Rouvière1.   

Abstract

Since there are salvage solutions, it is important to detect local recurrence of prostate cancer as early as possible. The first sign is "biochemical failure" in that the prostate specific antigen (PSA) concentration rises again. The definition of biochemical failure varies depending on the initial treatment: PSA greater than 0.2ng/mL after prostatectomy, nadir+2ng/mL after radiotherapy. There is no standardised definition of biochemical failure after cryotherapy, focused ultrasound, or brachytherapy. Magnetic resonance imaging (MRI) (particularly dynamic MRI) can detect local recurrence with good sensitivity. The role of spectroscopy is still under discussion. For the moment, ultrasound techniques are less effective than MRI.
Copyright © 2012 Éditions française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22464995     DOI: 10.1016/j.diii.2012.01.012

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  7 in total

1.  A Domain Constrained Deformable (DoCD) Model for Co-registration of Pre- and Post-Radiated Prostate MRI.

Authors:  Robert Toth; Bryan Traughber; Rodney Ellis; John Kurhanewicz; Anant Madabhushi
Journal:  Neurocomputing       Date:  2014-11-20       Impact factor: 5.719

2.  (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

Authors:  Cristina Nanni; Lucia Zanoni; Cristian Pultrone; Riccardo Schiavina; Eugenio Brunocilla; Filippo Lodi; Claudio Malizia; Matteo Ferrari; Patrizio Rigatti; Cristina Fonti; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-10       Impact factor: 9.236

3.  The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.

Authors:  Niranjan J Sathianathen; Mohit Butaney; Badrinath R Konety
Journal:  World J Urol       Date:  2018-07-12       Impact factor: 4.226

4.  Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT.

Authors:  Vivek Verma; Ling Chen; Jeff M Michalski; Yanle Hu; Wenjun Zhang; Kathryn Robinson; Shivam Verma; Laura Eschen; Sandra Fergus; Dan Mullen; Seth Strope; Robert Grubb; Hiram A Gay
Journal:  World J Urol       Date:  2014-03-20       Impact factor: 4.226

5.  Focal HIFU therapy for anterior compared to posterior prostate cancer lesions.

Authors:  Philipp M Huber; Naveed Afzal; Manit Arya; Silvan Boxler; Tim Dudderidge; Mark Emberton; Stephanie Guillaumier; Richard G Hindley; Feargus Hosking-Jervis; Lucas Leemann; Henry Lewi; Neil McCartan; Caroline M Moore; Raj Nigam; Chris Odgen; Raj Persad; Jaspal Virdi; Mathias Winkler; Hashim U Ahmed
Journal:  World J Urol       Date:  2020-07-07       Impact factor: 4.226

Review 6.  Contrast-Enhanced Transrectal Ultrasound in Focal Therapy for Prostate Cancer.

Authors:  Akbar N Ashrafi; Nima Nassiri; Inderbir S Gill; Mittul Gulati; Daniel Park; Andre L de Castro Abreu
Journal:  Curr Urol Rep       Date:  2018-08-28       Impact factor: 2.862

7.  A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Authors:  Massimo Valerio; Louise Dickinson; Afia Ali; Navin Ramachandran; Ian Donaldson; Alex Freeman; Hashim U Ahmed; Mark Emberton
Journal:  Contemp Clin Trials       Date:  2014-07-26       Impact factor: 2.226

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.